Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 17/20 | 1.00 |
| ▸ | DRD2 | P14416 | 13/20 | 1.00 |
| ▸ | DRD3 | P35462 | 9/20 | 1.00 |
| ▸ | DRD5 | P21918 | 5/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.91 |
| ▸ | DRD4 | P21917 | 2/20 | 0.91 |
| ▸ | F3 | P13726 | 5/20 | 0.89 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.87 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.87 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
| ▸ | HTR1A | P08908 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | CASP1 | P29466 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | APAF1 | O14727 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29999180 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD3DRD5SIGMAR1 | |
| SCHEMBL21192511 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD3DRD5SIGMAR1 | |
| SCHEMBL231003 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD3DRD5SIGMAR1 | |
| SCHEMBL16035972 | 0.95 | DRD1 (1.00) | DRD1DRD2DRD3DRD5SIGMAR1 | |
| SCHEMBL14703846 | 0.95 | DRD1 (1.00) | DRD1DRD2DRD3DRD5SIGMAR1 | |
| SCHEMBL680031 | 0.95 | DRD1 (1.00) | DRD1DRD2DRD3DRD5SIGMAR1 | |
| SCHEMBL29561422 | 0.95 | DRD1 (1.00) | DRD1DRD2DRD3DRD5SIGMAR1 | |
| SCHEMBL13334113 | 0.94 | DRD1 (1.00) | DRD1DRD2DRD3DRD5SIGMAR1 | |
| Hydrochloric Acid SCHEMBL3321082 | 0.93 | DRD1 (0.98) | DRD1DRD2DRD3DRD5SIGMAR1 | |
| SCHEMBL2742673 | 0.91 | DRD1 (0.85) | DRD1DRD2DRD3DRD5SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2022-12-08 | — | — | US | disclosed |
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2022-12-08 | — | — | US | disclosed |
| WO-2021067490-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2021-04-08 | — | — | WO | disclosed |
| US-20170100389-A1 | TETRAHYDROPROTOBERBINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | MILLER JAMES JACKSON (CA) | 2017-04-13 | — | — | US | disclosed |
| US-9526721-B2 | Tetrahydroprotoberbine compounds and uses thereof in the treatment of neurological, psychiatric and neurodegenerative diseases | MILLER JAMES JACKSON (CA) | 2016-12-27 | — | — | US | disclosed |
| US-20150306092-A1 | TETRAHYDROPROTOBERBINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | MILLER JAMES JACKSON (CA) | 2015-10-29 | — | — | US | disclosed |
| US-8815900-B2 | Compounds and compositions for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-08-26 | — | — | US | disclosed |
| US-8815900-B2 | Compounds and compositions for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-08-26 | — | — | US | disclosed |
| US-8710071-B2 | Compounds, compositions and methods for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-04-29 | — | — | US | disclosed |
| US-8710071-B2 | Compounds, compositions and methods for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-04-29 | — | — | US | disclosed |
| US-20110269754-A1 | COMPOUNDS AND COMPOSITIONS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2011-11-03 | — | — | US | disclosed |
| US-8003795-B2 | Compounds and compositions for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2011-08-23 | — | — | US | disclosed |
| US-8003795-B2 | Compounds and compositions for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2011-08-23 | — | — | US | disclosed |
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | CVI PHARMACEUTICALS LIMITED (KY) | 2011-01-13 | — | — | US | disclosed |
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | CVI PHARMACEUTICALS LIMITED (KY) | 2011-01-13 | — | — | US | disclosed |
| WO-2011006000-A1 | BERBERINE DERIVATIVES USEFUL FOR MODULATING LIPID LEVELS AND THEIR METHODS OF SYNTHESIS | LIU HAIYAN (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010075469-A1 | CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2010-07-01 | — | — | WO | disclosed |
| US-20090048246-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2009-02-19 | — | — | US | disclosed |
| US-20090048246-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2009-02-19 | — | — | US | disclosed |
| WO-2009002873-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | LIPC, LDLR, PCSK9 | DRD1 4873/4885DRD2 4863/4885DRD3 4832/4885 |
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | LIPC, FABP1, CPT1A | DRD1 4727/4885DRD2 4557/4885DRD3 4182/4885 |
| US-20170100389-A1 | TETRAHYDROPROTOBERBINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | HTR1B, HTR2B, MAOB | DRD1 124/4885DRD2 63/4885DRD3 258/4885 |
| US-20110269754-A1 | COMPOUNDS AND COMPOSITIONS FOR REDUCING LIPID LEVELS | LIPC, LIPE, BCHE | DRD1 465/4885DRD2 139/4885DRD3 532/4885 |
| US-20150306092-A1 | TETRAHYDROPROTOBERBINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | HTR1B, HTR2B, MAOB | DRD1 119/4885DRD2 64/4885DRD3 259/4885 |
| US-20090048246-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | LIPC, BCHE, LIPE | DRD1 553/4885DRD2 175/4885DRD3 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.